

Special Issue

Research and Significance of Vaccines Against Sexually Transmitted Diseases

Message from the Guest Editors

Vaccines represent a cornerstone in the prevention of sexually transmitted infections (STIs). Currently, three STIs have approved vaccines: human papillomavirus (HPV), hepatitis B virus (HBV), and hepatitis A virus (HAV). These vaccines have demonstrated significant public health impact by preventing HPV-related cancers and genital warts, HBV-related liver disease, and sexually transmitted HAV outbreaks, particularly among men who have sex with men (MSM). However, barriers such as low coverage, misinformation, and access inequities continue to limit their potential.

This Special Issue invites original research, reviews, and commentary focused exclusively on approved STI vaccines. Topics may include vaccine effectiveness, uptake disparities, implementation strategies, population-specific interventions, and policy innovations. Research areas may include but are not limited to the following:

- **Synthesizing current evidence on the use and impact of approved STI vaccines**
- **Identifying strategies to improve vaccine uptake and equity**
- **Informing future public health and clinical efforts**

Guest Editors

Prof. Dr. Angela Chia-Chen Chen

College of Nursing, Michigan State University, 1355 Bogue St, East Lansing, MI 48824, USA

Prof. Dr. Elizabeth Reifsnider

1. College of Nursing and Health Innovation, Arizona State University, Tempe, Phoenix, AZ 85004, USA

2. Ellmer School of Nursing, Old Dominion University, Virginia Beach, VA, USA

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/242955

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).